Organisation paid for research Program year 2023 Source: CMS Open Payments

Q-Way Research LLC

Neither a doctor nor a teaching hospital

Research payments

$793,377

811 payments

Through program year 2023, Q-Way Research LLC is reported as receiving $793,377 in research payments, across 811 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$40,871	2
2022	Research	$66,149	127
2021	Research	$76,987	149
2020	Research	$292,852	115
2019	Research	$316,518	418

Breakdown

Who paid Research payments · program years 2019–2023

Akebia Therapeutics Inc $594,766 459 payments
Esperion Therapeutics, Inc. $198,611 352 payments

Studies the money was for Research payments · program years 2019–2023

Akb-6548-Ci-0014 $279,291 364 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $246,210 21 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $198,611 352 payments
Akb-6548-Ci-0015 $37,227 54 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $20,040 19 payments
Akb-6548-Ci-0015 $11,997 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.